Xilio Ther­a­peu­tics eyes the fast track to the clin­ic with $95M in in­vestor cash to test re­designed IL-2, CT­LA-4 meds

About three years af­ter join­ing the search for IL-2  and CT­LA-4 ther­a­pies with­out all those nasty side ef­fects, Xilio Ther­a­peu­tics has teed up $95 mil­lion to dri­ve its two lead can­di­dates in­to the clin­ic.

The Se­ries C round was led by Rock Springs Cap­i­tal, and should al­low the small Waltham, Mass­a­chu­setts-based biotech to file INDs for XTX101, its an­ti-CT­LA-4 an­ti­body, in Q2 and XTX202, its IL-2 ag­o­nist, in Q3.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER